The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chaperot, L.
Right arrow Articles by Plumas, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaperot, L.
Right arrow Articles by Plumas, J.
The Journal of Immunology, 2006, 176: 248-255.
Copyright © 2006 by The American Association of Immunologists

Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells1

Laurence Chaperot2,3, Ariane Blum2, Olivier Manches, Gabrielle Lui, Juliette Angel, Jean-Paul Molens and Joël Plumas

Department of Research and Development, Etablissement Français du Sang Rhône-Alpes Grenoble, La Tronche, France

Among dendritic cells, plasmacytoid dendritic cells (PDC) represent a functionally distinct lineage. Regarding innate immunity, PDC secrete large amounts of type I IFN upon viral exposure or stimulation by microbial products such as unmethylated CpG-motif containing oligo-DNA due to their selective expression of TLR7 and TLR9. We asked whether they could acquire cytotoxic functions during the early phases of infection or after activation with TLR7 or TLR9 agonists. In the present study, we describe a human PDC cell line called GEN2.2, derived from leukemic PDC, that shares most of the phenotypic and functional features of normal PDC. We show that after contact with the influenza virus, GEN2.2, as well as normal PDC, acquires TRAIL and killer activity against TRAIL-sensitive target cells. Moreover, we show that activation of GEN2.2 cells by CpG-motif containing oligo-DNA or R848 also induces TRAIL and endows them with the ability to kill melanoma cells. Therefore, PDC may represent a major component of innate immunity that could participate to the clearance of infected cells and tumor cells. This phenomenon could be relevant for the efficacy of TLR7 or TLR9 agonists in the therapy of infectious disease and cancer.




This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
B. M. Burt, G. Plitas, J. A. Stableford, H. M. Nguyen, Z. M. Bamboat, V. G. Pillarisetty, and R. P. DeMatteo
CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis
J. Leukoc. Biol., October 1, 2008; 84(4): 1039 - 1046.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. L. Brincks, A. Katewa, T. A. Kucaba, T. S. Griffith, and K. L. Legge
CD8 T Cells Utilize TRAIL to Control Influenza Virus Infection
J. Immunol., October 1, 2008; 181(7): 4918 - 4925.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Chauvin and R. Josien
Dendritic Cells as Killers: Mechanistic Aspects and Potential Roles
J. Immunol., July 1, 2008; 181(1): 11 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. W. Hardy, D. R. Graham, G. M. Shearer, and J.-P. Herbeuval
HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-{alpha}
PNAS, October 30, 2007; 104(44): 17453 - 17458.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
U. I. Chaudhry, G. Plitas, B. M. Burt, T. P. Kingham, J. R. Raab, and R. P. DeMatteo
NK Dendritic Cells Expanded in IL-15 Exhibit Antitumor Responses In Vivo
J. Immunol., October 1, 2007; 179(7): 4654 - 4660.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. M. Whitmore, A. Iparraguirre, L. Kubelka, W. Weninger, T. Hai, and B. R. G. Williams
Negative Regulation of TLR-Signaling Pathways by Activating Transcription Factor-3
J. Immunol., September 15, 2007; 179(6): 3622 - 3630.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
G. Stary, C. Bangert, M. Tauber, R. Strohal, T. Kopp, and G. Stingl
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
J. Exp. Med., June 11, 2007; 204(6): 1441 - 1451.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. G. Molenkamp, P. A.M. van Leeuwen, S. Meijer, B. J.R. Sluijter, P. G.J.T.B. Wijnands, A. Baars, A. J.M. van den Eertwegh, R. J. Scheper, and T. D. de Gruijl
Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients
Clin. Cancer Res., May 15, 2007; 13(10): 2961 - 2969.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
U. I. Chaudhry, T. P. Kingham, G. Plitas, S. C. Katz, J. R. Raab, and R. P. DeMatteo
Combined Stimulation with Interleukin-18 and CpG Induces Murine Natural Killer Dendritic Cells to Produce IFN-{gamma} and Inhibit Tumor Growth
Cancer Res., November 1, 2006; 66(21): 10497 - 10504.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Fabricius, M. S. O'Dorisio, S. Blackwell, and B. Jahrsdorfer
Human Plasmacytoid Dendritic Cell Function: Inhibition of IFN-{alpha} Secretion and Modulation of Immune Phenotype by Vasoactive Intestinal Peptide
J. Immunol., November 1, 2006; 177(9): 5920 - 5927.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. A. Cassatella
On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils
J. Leukoc. Biol., June 1, 2006; 79(6): 1140 - 1149.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.